|Articles|March 11, 2021
- Pharmaceutical Executive-03-01-2021
- Volume 41
- Issue 3
Pharmaceutical Executive, March 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
The Amazon Effect: A Data-Fueled Customer Experienceover 5 years ago
Why ESG Performance Metrics Matterover 5 years ago
Pharma and Biotech’s 2020 Full-Year Viewover 5 years ago
Persevering for Patientsover 5 years ago
Biopharma’s Reputation Gets a Well-Earned Shot in the Armover 5 years ago
IP and Capitalover 5 years ago
IP and COVID-19over 5 years ago
Pharma Steps Up for Public Health Inequitiesover 5 years ago
FDA Relays Recent Achievements, Maps Plans for Progressover 5 years ago
IP and CollaborationAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
2
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
3
The New Healthy Aging Imperative and What It Means for Pharma
4
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
5